Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 55 (5), 1112-1123
- https://doi.org/10.1016/j.eururo.2008.11.002
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancerExpert Opinion on Investigational Drugs, 2008
- A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancerCancer, 2007
- The hazards of intermediate endpointsCancer, 2007
- The changing pattern of management for hormone-refractory, metastatic prostate cancerProstate Cancer and Prostatic Diseases, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Endothelin Expression and the Progression of Heart FailureCirculation, 2004
- Bisphosphonates to Prevent Skeletal Complications in Men With Metastatic Prostate CancerJournal of Urology, 2003
- Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled TrialJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994